SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 84 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,952,417 | -17.1% | 134,464 | +19.6% | 0.23% | -7.7% |
Q2 2023 | $2,353,872 | +17.1% | 112,464 | +18.1% | 0.25% | +2.9% |
Q1 2023 | $2,010,814 | +23.1% | 95,209 | +48.3% | 0.24% | 0.0% |
Q4 2022 | $1,634,068 | +7.0% | 64,207 | +1.0% | 0.24% | +16.0% |
Q3 2022 | $1,527,000 | +31.1% | 63,551 | +5.0% | 0.21% | +35.5% |
Q2 2022 | $1,165,000 | +5.5% | 60,551 | -4.7% | 0.15% | +15.2% |
Q1 2022 | $1,104,000 | +348.8% | 63,516 | +81.3% | 0.13% | +407.7% |
Q2 2018 | $246,000 | -52.9% | 35,027 | -4.6% | 0.03% | -60.0% |
Q1 2018 | $522,000 | -28.3% | 36,714 | -55.8% | 0.06% | -13.3% |
Q4 2017 | $728,000 | +16.3% | 83,139 | +55.3% | 0.08% | -13.8% |
Q3 2017 | $626,000 | -19.0% | 53,532 | -3.3% | 0.09% | -16.3% |
Q2 2017 | $773,000 | – | 55,368 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |